Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SELLAS Life Sciences GroupSLS +12.35%25 3-Year EBITDA Growth Rate is 46.00% as of Mar. 2026, which is 10% above its 10-year median of 41.70. GuruFocus rates SLS with a GF Score™ of 25/100. Among 1,137 Biotechnology companies, SELLAS Life Sciences Group ranks better than 82.32% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 46.00% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 31.90% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 62.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of SELLAS Life Sciences Group was 83.10% per year. The lowest was 3.90% per year. And the median was 41.70% per year.
SELLAS Life Sciences Group (NAS:SLS) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
SELLAS Life Sciences Group 3-Year EBITDA Growth Rate Related Terms
SLS vs MBX, BHVN, PHVS: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, SELLAS Life Sciences Group's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SELLAS Life Sciences Group 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SELLAS Life Sciences Group's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where SELLAS Life Sciences Group's 3-Year EBITDA Growth Rate falls into.
SELLAS Life Sciences Group 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 46.00% mean?
SELLAS Life Sciences Group (SLS) has a 3-Year EBITDA Growth Rate of 46.00% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for SELLAS Life Sciences Group and its competitors. This is 10% above median its historical median of 41.70. Over the past decade, SELLAS Life Sciences Group's 3-Year EBITDA Growth Rate has ranged from 3.90 to 83.10. According to the industry distribution chart, SELLAS Life Sciences Group ranks #201 out of 1137 companies in the Biotechnology industry, placing it in the top 17.7%.
Is SELLAS Life Sciences Group's 3-Year EBITDA Growth Rate too high?
SELLAS Life Sciences Group's current 3-Year EBITDA Growth Rate of 46.00% is 10% above median its 10-year median of 41.70. Over the past 10 years, this metric has ranged from a low of 3.90 to a high of 83.10. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.90. SELLAS Life Sciences Group's value of 46.00% is 208.7% above this industry median. Based on the distribution chart, SELLAS Life Sciences Group ranks #201 out of 1137 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, SELLAS Life Sciences Group has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does SELLAS Life Sciences Group's 3-Year EBITDA Growth Rate compare to MBX and BHVN?
According to the Biotechnology industry distribution chart, SELLAS Life Sciences Group ranks #201 out of 1137 companies for 3-Year EBITDA Growth Rate. This places SELLAS Life Sciences Group in the top 18% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.90. SELLAS Life Sciences Group's value of 46.00% is 208.7% above this benchmark. Historically, SELLAS Life Sciences Group's own 3-Year EBITDA Growth Rate has ranged from 3.90 to 83.10 over the past decade. While the company's 10-year median is 41.70 vs. the industry median of 14.90, SELLAS Life Sciences Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,137 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SELLAS Life Sciences Group's current 3-Year EBITDA Growth Rate of 46.00% is 208.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for SELLAS Life Sciences Group and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SELLAS Life Sciences Group's current 3-Year EBITDA Growth Rate is 46.00%, which is 10% above median its own 10-year median of 41.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SELLAS Life Sciences Group stock overvalued right now?
SELLAS Life Sciences Group (SLS) has a current 3-Year EBITDA Growth Rate of 46.00%. The current 3-Year EBITDA Growth Rate is 46.00%, which is 10% above median its 10-year median of 41.70 and 208.7% above the Biotechnology industry median of 14.90. SELLAS Life Sciences Group's overall GF Score™ is 25/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For SELLAS Life Sciences Group (SLS), the current 3-Year EBITDA Growth Rate is 46.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
25GF Score
Get the complete analysis for SLS
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SLS has been successfully added to your 
